0001209191-19-034236.txt : 20190604 0001209191-19-034236.hdr.sgml : 20190604 20190604161525 ACCESSION NUMBER: 0001209191-19-034236 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190601 FILED AS OF DATE: 20190604 DATE AS OF CHANGE: 20190604 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCGLYNN MARGARET G CENTRAL INDEX KEY: 0001215126 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 19876764 MAIL ADDRESS: STREET 1: C/O MERCK & CO INC STREET 2: ONE MERCK DRIVE PO BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-01 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001215126 MCGLYNN MARGARET G C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 Common Stock 2019-06-01 4 D 0 1801 D 4124 D Stock Option (Right to Buy) 168.04 2019-06-01 4 A 0 6659 0.00 A 2029-05-31 Common Stock 6659 6659 D Deferred Stock Units 2019-06-01 4 A 0 1801 A Common Stock 1801 3989 D Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2018, Ms. McGlynn deferred the receipt of 1,801 shares of common stock and received instead 1,801 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 1,801 shares of common stock in exchange for an equal number of deferred stock units. Fully vested. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death. /s/ Omar White, Attorney-in-Fact 2019-06-04